BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 8675423)

  • 1. Functional hepatobiliary imaging with gadolinium-EOB-DTPA. A comparison of magnetic resonance imaging and 153gadolinium-EOB-DTPA scintigraphy in rats.
    Schmitz SA; Mühler A; Wagner S; Wolf KJ
    Invest Radiol; 1996 Mar; 31(3):154-60. PubMed ID: 8675423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
    Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
    Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic kinetics and magnetic resonance imaging of gadolinium-EOB-DTPA in dogs.
    Benness G; Khangure M; Morris I; Warwick A; Burrows P; Vogler H; Weinmann HJ
    Invest Radiol; 1996 Apr; 31(4):211-7. PubMed ID: 8721960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA.
    Vogl TJ; Kümmel S; Hammerstingl R; Schellenbeck M; Schumacher G; Balzer T; Schwarz W; Müller PK; Bechstein WO; Mack MG; Söllner O; Felix R
    Radiology; 1996 Jul; 200(1):59-67. PubMed ID: 8657946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MR imaging evaluation of liver enhancement by Gd-EOB-DTPA in selective and total bile duct obstruction in rats: correlation with serologic, microcholangiographic, and histologic findings.
    Ni Y; Marchal G; Lukito G; Yu J; Mühler A; Baert AL
    Radiology; 1994 Mar; 190(3):753-8. PubMed ID: 8115623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gd-EOB-DTPA enhancement pattern of hepatocellular carcinomas in rats: comparison with Tc-99m-IDA uptake.
    Van Beers BE; Grandin C; Pauwels S; Mottet I; Goudemant JF; Delos M; Demeure R; Pringot J
    J Magn Reson Imaging; 1994; 4(3):351-4. PubMed ID: 8061433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.
    Hamm B; Staks T; Mühler A; Bollow M; Taupitz M; Frenzel T; Wolf KJ; Weinmann HJ; Lange L
    Radiology; 1995 Jun; 195(3):785-92. PubMed ID: 7754011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
    Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
    Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancements in hepatobiliary imaging: the spectrum of gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid usages in hepatobiliary magnetic resonance imaging.
    Channual S; Pahwa A; Lu DS; Raman SS
    Abdom Radiol (NY); 2016 Sep; 41(9):1825-41. PubMed ID: 27225503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Gd-EOB-DTPA and Gd-DTPA for contrast-enhanced MR imaging of liver tumors.
    Clemént O; Mühler A; Vexler VS; Kuwatsuru R; Berthezène Y; Rosenau W; Brasch RC
    J Magn Reson Imaging; 1993; 3(1):71-7. PubMed ID: 8428104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of gadolinium-ethoxybenzyl-DTPA in a rat model of severely impaired liver and kidney excretory function. An experimental study in rats.
    Mühler A; Heinzelmann I; Weinmann HJ
    Invest Radiol; 1994 Feb; 29(2):213-6. PubMed ID: 8169100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA.
    Kim T; Murakami T; Hasuike Y; Gotoh M; Kato N; Takahashi M; Miyazawa T; Narumi Y; Monden M; Nakamura H
    J Magn Reson Imaging; 1997; 7(4):683-8. PubMed ID: 9243389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging.
    Reimer P; Rummeny EJ; Daldrup HE; Hesse T; Balzer T; Tombach B; Peters PE
    Eur Radiol; 1997; 7(2):275-80. PubMed ID: 9038130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging.
    Tsuda N; Okada M; Murakami T
    Invest Radiol; 2007 Apr; 42(4):242-7. PubMed ID: 17351431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatobiliary enhancement with Gd-EOB-DTPA: comparison of spin-echo and STIR imaging for detection of experimental liver metastases.
    Mühler A; Clément O; Vexler V; Berthezène Y; Rosenau W; Brasch RC
    Radiology; 1992 Jul; 184(1):207-13. PubMed ID: 1609081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence.
    Reimer P; Rummeny EJ; Shamsi K; Balzer T; Daldrup HE; Tombach B; Hesse T; Berns T; Peters PE
    Radiology; 1996 Apr; 199(1):177-83. PubMed ID: 8633143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring hepatic functional reserve using T1 mapping of Gd-EOB-DTPA enhanced 3T MR imaging: A preliminary study comparing with
    Nakagawa M; Namimoto T; Shimizu K; Morita K; Sakamoto F; Oda S; Nakaura T; Utsunomiya D; Shiraishi S; Yamashita Y
    Eur J Radiol; 2017 Jul; 92():116-123. PubMed ID: 28624009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged positive contrast enhancement with Gd-EOB-DTPA in experimental liver tumors: potential value in tissue characterization.
    Ni Y; Marchal G; Yu J; Mühler A; Lukito G; Baert AL
    J Magn Reson Imaging; 1994; 4(3):355-63. PubMed ID: 8061434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic contrast-enhanced MRI of the liver in Mrp2-deficient rats using the hepatobiliary contrast agent Gd-EOB-DTPA.
    Saito S; Obata A; Kashiwagi Y; Abe K; Murase K
    Invest Radiol; 2013 Jul; 48(7):548-53. PubMed ID: 23442774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadolinium-ethoxybenzyl-DTPA, a new liver-directed magnetic resonance contrast agent. Absence of acute hepatotoxic, cardiovascular, or immunogenic effects.
    Mühler A; Clément O; Saeed M; Lake JR; Stites DP; Berthezène Y; Brasch RC
    Invest Radiol; 1993 Jan; 28(1):26-32. PubMed ID: 8425849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.